These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 39291715

  • 21. UK consensus statement on the use of plerixafor to facilitate autologous peripheral blood stem cell collection to support high-dose chemoradiotherapy for patients with malignancy.
    Douglas KW, Gilleece M, Hayden P, Hunter H, Johnson PRE, Kallmeyer C, Malladi RK, Paneesha S, Pawson R, Quinn M, Raj K, Richardson D, Robinson S, Russell N, Snowden J, Sureda A, Tholouli E, Thomson K, Watts M, Wilson KM.
    J Clin Apher; 2018 Feb; 33(1):46-59. PubMed ID: 28631842
    [Abstract] [Full Text] [Related]

  • 22. Predictive factors for peripheral blood stem cell mobilization in multiple myeloma in the era of novel therapies: A single-center experience.
    He X, Jiang D, Zhao L, Chen S, Zhu Y, He Q, He Y.
    Cancer Med; 2024 Jun; 13(11):e7356. PubMed ID: 38850125
    [Abstract] [Full Text] [Related]

  • 23. Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization.
    Costa LJ, Alexander ET, Hogan KR, Schaub C, Fouts TV, Stuart RK.
    Bone Marrow Transplant; 2011 Jan; 46(1):64-9. PubMed ID: 20383210
    [Abstract] [Full Text] [Related]

  • 24. Incidence and risk factors of poor mobilization in adult autologous peripheral blood stem cell transplantation: a single-centre experience.
    Lee KH, Jung SK, Kim SJ, Jang JH, Kim K, Kim WS, Jung CW, Kim DW, Kang ES.
    Vox Sang; 2014 Nov; 107(4):407-15. PubMed ID: 25130876
    [Abstract] [Full Text] [Related]

  • 25. Comparison and cost analysis of three protocols for mobilization and apheresis of haematopoietic progenitor cells.
    López-Castaño F, Manresa P, Díaz V, Arranz E, López J, Pérez M, Alda O, Hernández L.
    J Clin Apher; 2019 Aug; 34(4):461-467. PubMed ID: 30817045
    [Abstract] [Full Text] [Related]

  • 26. Plerixafor added to G-CSF-supported paclitaxel-ifosfamide-cisplatin salvage chemotherapy enhances mobilization of adequate numbers of hematopoietic stem cells for subsequent autografting in hard-to-mobilize patients with relapsed/refractory germ-cell tumors: a single-center experience.
    Kosmas C, Athanasopoulos A, Dimitriadis G, Miltiadous C, Zilakos M, Lydakis D, Magiorkinis E, Gekas C, Daladimos T, Mylonakis N, Ziras N.
    Anticancer Drugs; 2014 Aug; 25(7):841-7. PubMed ID: 24625457
    [Abstract] [Full Text] [Related]

  • 27. Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program.
    Hübel K, Fresen MM, Salwender H, Basara N, Beier R, Theurich S, Christopeit M, Bogner C, Galm O, Hartwig R, Heits F, Lordick F, Rösler W, Wehler D, Zander AR, Albert MH, Dressler S, Ebinger M, Frickhofen N, Hertenstein B, Kiehl M, Liebler S, von Lilienfeld-Toal M, Weidmann E, Weigelt C, Lange F, Kröger N.
    Bone Marrow Transplant; 2011 Aug; 46(8):1045-52. PubMed ID: 20972470
    [Abstract] [Full Text] [Related]

  • 28. The CXCR4 and adhesion molecule expression of CD34+ hematopoietic cells mobilized by "on-demand" addition of plerixafor to granulocyte-colony-stimulating factor.
    Girbl T, Lunzer V, Greil R, Namberger K, Hartmann TN.
    Transfusion; 2014 Sep; 54(9):2325-35. PubMed ID: 24673458
    [Abstract] [Full Text] [Related]

  • 29. Impact of plerixafor (mozobil) on hospital efficiency: A single center experience.
    Azar N, Ouzegdouh M, Choquet S, Leblond V.
    J Clin Apher; 2018 Feb; 33(1):5-13. PubMed ID: 28455878
    [Abstract] [Full Text] [Related]

  • 30. Efficacy of just-in-time plerixafor rescue for Hodgkin's lymphoma patients with poor peripheral blood stem cell mobilization.
    Yuan S, Nademanee A, Kaniewski M, Palmer J, Shayani S, Wang S.
    Transfusion; 2014 Aug; 54(8):2015-21. PubMed ID: 24660786
    [Abstract] [Full Text] [Related]

  • 31. Experience with plerixafor for hematopoietic cell mobilization in nine patients with germ cell tumors.
    Daphne O'Hara VJ, Karr AH, Srivastava S, Kiel PJ.
    Pharmacotherapy; 2014 Jan; 34(1):85-8. PubMed ID: 23864559
    [Abstract] [Full Text] [Related]

  • 32. Plerixafor in poor mobilizers with non-Hodgkin's lymphoma: a multi-center time-motion analysis.
    Mohty M, Azar N, Chabannon C, Le Gouill S, Karlin L, Farina L, Milkovich G, Ostermann H, Glaß B, Noppeney R, Kron F, Kron A, Hübel K.
    Bone Marrow Transplant; 2018 Mar; 53(3):246-254. PubMed ID: 29255168
    [Abstract] [Full Text] [Related]

  • 33. Plerixafor strategies for autologous hematopoietic cell transplant mobilization: A comparison of efficacy and cost.
    Chen KY, Bucci TG, Shaw JR, Alexander MD, Grgic T, Riches M, Ptachcinski JR.
    Transfus Apher Sci; 2022 Apr; 61(2):103303. PubMed ID: 34801430
    [Abstract] [Full Text] [Related]

  • 34. [Efficacy and Safety of Plerixafor Combined with G-CSF for Autologous Peripheral Blood Hematopoietic Stem Cell Mobilization in Lymphoma Patients].
    Guan FS, He DH, Li Y, Zhang Y, Zheng GF, Zhu YY, He JS, Zhang EF, Cai Z, Zhao Y.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Aug; 31(4):1056-1060. PubMed ID: 37551477
    [Abstract] [Full Text] [Related]

  • 35. Who should be really considered as a poor mobilizer in the plerixafor era?
    Andreola G, Vanazzi A, Radice D, Babic A, Rabascio C, Negri M, Martinelli G, Laszlo D.
    Transfus Apher Sci; 2012 Aug; 47(1):27-32. PubMed ID: 22480954
    [Abstract] [Full Text] [Related]

  • 36. Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF.
    Chaudhary L, Awan F, Cumpston A, Leadmon S, Watkins K, Tse W, Craig M, Hamadani M.
    J Clin Apher; 2013 Oct; 28(5):359-67. PubMed ID: 23765597
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. [A Single-Center Analysis of the Use of G-CSF Combined with Plerixafor to Mobilize Peripheral Blood Hematopoietic Stem Cell from Healthy Related Donors in Allogeneic Hematopoietic Stem Cell Transplantation].
    Chen J, Yuan LL, Zhang X, Qiao JL, Yin QX, Zhang YM, Yang XL, Cao XY.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):286-291. PubMed ID: 35123641
    [Abstract] [Full Text] [Related]

  • 39. G-CSF plus preemptive plerixafor vs hyperfractionated CY plus G-CSF for autologous stem cell mobilization in multiple myeloma: effectiveness, safety and cost analysis.
    Antar A, Otrock ZK, Kharfan-Dabaja MA, Ghaddara HA, Kreidieh N, Mahfouz R, Bazarbachi A.
    Bone Marrow Transplant; 2015 Jun; 50(6):813-7. PubMed ID: 25751646
    [Abstract] [Full Text] [Related]

  • 40. Successful peripheral blood stem cell mobilization with a cost-efficient single fixed-dose plerixafor schedule in poor mobilizers.
    Greil C, Kiote-Schmidt C, Fink G, Ihorst G, Hildenbeutel S, Bosse R, Duyster J, Engelhardt M, Wäsch R.
    Leuk Lymphoma; 2017 Aug; 58(8):1849-1858. PubMed ID: 28084849
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.